Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2015

01-12-2015

A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye

Authors: Nathalie Costedoat-Chalumeau, Bertrand Dunogué, Gaëlle Leroux, Nathalie Morel, Moez Jallouli, Véronique Le Guern, Jean-Charles Piette, Antoine P. Brézin, Ronald B. Melles, Michael F. Marmor

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2015

Login to get access

Abstract

Hydroxychloroquine (HCQ) and chloroquine have been used for more than 50 years to treat systemic lupus erythematosus (SLE) and other rheumatic diseases. In general, these drugs are well tolerated and rarely need to be discontinued because of an adverse systemic reaction. However, both medications can be irreversibly toxic to the retina. A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors. With attention to dosage and other factors, and with proper screening for early signs of toxicity, HCQ can be prescribed with relative safety even over long periods of time.
Literature
1.
Costedoat-Chalumeau N, Leroux G, Piette J-C, Amoura Z (2010) Antimalarials and systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon JP, Koike T (eds) Systemic lupus erythematosus, 5th edn. Elsevier, 1061–1081
2.
Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583CrossRefPubMed
3.
Alarcon GS, McGwin G Jr, Bertoli AM et al (2007) Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic us cohort (LUMINA L). Ann Rheum Dis 66:1168–1172PubMedCentralCrossRefPubMed
4.
Shinjo SK, Bonfa E, Wojdyla D et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855–862CrossRefPubMed
5.
Costedoat-Chalumeau N, Hulot JS, Amoura Z et al (2006) Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107:73–80CrossRefPubMed
6.
Melles RB, Marmor MF (2014) The risk of toxic retinopathy in long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460CrossRefPubMed
7.
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–422CrossRefPubMed
8.
Marmor MF, Hu J (2014) Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 132:1105–1112CrossRefPubMed
9.
Yam JC, Kwok AK (2006) Ocular toxicity of hydroxychloroquine. Hong Kong Med J 12:294–304PubMed
10.
11.
Dosso A, Rungger-Brandle E (2007) In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 245:318–320CrossRefPubMed
12.
Tehrani R, Ostrowski RA, Hariman R, Jay WM (2008) Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 23:201–209CrossRefPubMed
13.
Marmor MF (2012) Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 130:461–469CrossRefPubMed
14.
Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110-116
15.
Lee DH, Joe SG, Lee JY, Kim J-G, Lee CG, Yoo B, Koo BS, Melles RB, Marmor, MF, Yoon, YH (2015) Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology (in press)
16.
Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62:775–784CrossRef
17.
Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75:40–45CrossRefPubMed
18.
Bergholz R, Schroeter J, Ruther K (2010) Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol 94:1637–1642CrossRefPubMed
19.
Easterbrook M (2002) Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 37:325–328CrossRefPubMed
20.
Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA (2013) Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 131:1187–1197CrossRefPubMed
21.
Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al (2013) Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 27:329–340CrossRefPubMed
22.
Costedoat-Chalumeau N, Galicier L, Aumaitre O et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72:1786–1792CrossRefPubMed
23.
Tett SE, Cutler DJ, Day RO (1992) Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci 81:155–159CrossRefPubMed
24.
Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE (2013) Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus 22:541–542CrossRefPubMed
25.
Shroyer NF, Lewis RA, Lupski JR (2001) Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 131:761–766CrossRefPubMed
26.
Munster T, Gibbs JP, Shen D et al (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46:1460–1469CrossRefPubMed
27.
Tett SE, Cutler DJ, Beck C, Day RO (2000) Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis—a prospective, dose ranging study. J Rheumatol 27:1656–1660PubMed
28.
Tett SE, Day RO, Cutler DJ (1993) Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. J Rheumatol 20:1874–1879PubMed
29.
Frances C, Cosnes A, Duhaut P et al (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148:479–484CrossRefPubMed
30.
Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284–3290CrossRefPubMed
31.
Carmichael SJ, Day RO, Tett SE (2013) A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 43:547–553CrossRefPubMed
32.
Ting TV, Kudalkar D, Nelson S et al (2012) Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 39:174–179CrossRefPubMed
33.
Costedoat-Chalumeau N, Le Guern V, Piette JC (2014) Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et Al. Arthritis Rheum 66:770CrossRef
34.
Alexander S, Chusney G, Chusney VD, Lee J, Cairns T, Lightstone L (2013) The Achilles heel of lupus nephritis treatment—identifying non adherence using hydroxychloroquine blood levels (abstract). J Am Soc Nephrol
35.
Petri M, Fand H, Clarke W (2013) Hydroxychloroquine levels identify four distinct subsets of systemic lupus erythematosus patients (abstract). Arthritis Rheum 65:S770CrossRef
36.
Jallouli M, Frances C, Piette JC et al (2013) Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 149:935–940CrossRefPubMed
37.
Carr RE, Henkind P, Rothfield N, Siegel IM (1968) Ocular toxicity of antimalarial drugs. Long-term follow-up. Am J Ophthalmol 66:738–744CrossRefPubMed
38.
Easterbrook M (1992) Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 27:237–239PubMed
39.
40.
41.
Kijlstra A, Tian Y, Kelly ER, Berendschot TT (2012) Lutein: more than just a filter for blue light. Prog Retin Eye Res 31:303–315CrossRefPubMed
42.
43.
Chew EY, Clemons TE, Sangiovanni JP et al (2014) Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 132:142–149PubMedCentralCrossRefPubMed
44.
Marmor MF, Hu J (2014) Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 132(9):1105–1112
45.
Marmor MF, Melles RB (2014) Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology 121:1257–1262CrossRefPubMed
46.
Missner S, Kellner U (2012) Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol 250:319–325CrossRefPubMed
47.
Rigaudiere F, Ingster-Moati I, Hache JC et al (2004) Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophtalmol 27:191–199CrossRefPubMed
48.
Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538CrossRefPubMed
49.
Lyons JS, Severns ML (2007) Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 143:801–809CrossRefPubMed
50.
Anderson C, Blaha GR, Marx JL (2011) Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond) 25:1535–1545CrossRef
51.
52.
Nika M, Blachley TS, Edwards P, Lee PP, Stein JD (2014) Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 132(10):1199–1208PubMedCentralCrossRefPubMed
53.
Costedoat-Chalumeau N, Amoura Z, Aymard G et al (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46:1123–1124CrossRefPubMed
54.
Parke A, West B (1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23:1715–1718PubMed
55.
Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR (1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 55:486–488PubMedCentralCrossRefPubMed
56.
Motta M, Tincani A, Faden D, Zinzini E, Chirico G (2002) Antimalarial agents in pregnancy. Lancet 359:524–525CrossRefPubMed
57.
Klinger G, Morad Y, Westall CA et al (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813–814CrossRefPubMed
58.
Levy RA, Vilela VS, Cataldo MJ et al (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401–404CrossRefPubMed
59.
Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54:3640–3647CrossRefPubMed
60.
Costedoat-Chalumeau N, Amoura Z, Duhaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48:3207–3211CrossRefPubMed
61.
Sperber K, Hom C, Chao CP, Shapiro D, Ash J (2009) Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 7:9PubMedCentralCrossRefPubMed
62.
Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A (2013) Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 39C:58–62CrossRef
63.
Cimaz R, Brucato A, Meregalli E, Muscara M, Sergi P (2004) Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum 50:3056–3057, author reply 3057–3058CrossRefPubMed
64.
Costedoat-Chalumeau N, Amoura Z, Sebbough D, Piette JC (2004) Reply. Arthritis Rheum 50:3057CrossRef
65.
Motta M, Tincani A, Faden D et al (2004) Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 14:14
66.
Renault F, Flores-Guevara R, Renaud C, Richard P, Vermersch AI, Gold F (2009) Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 98:1500–1503CrossRefPubMed
67.
Ingster-Moati I, Albuisson E (2010) Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 99:4, author reply 4–5CrossRefPubMed
68.
Osadchy A, Ratnapalan T, Koren G (2011) Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 38:2504–2508CrossRefPubMed
69.
Metadata
Title
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye
Authors
Nathalie Costedoat-Chalumeau
Bertrand Dunogué
Gaëlle Leroux
Nathalie Morel
Moez Jallouli
Véronique Le Guern
Jean-Charles Piette
Antoine P. Brézin
Ronald B. Melles
Michael F. Marmor
Publication date
01-12-2015
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2015
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8469-8

Other articles of this Issue 3/2015

Clinical Reviews in Allergy & Immunology 3/2015 Go to the issue

ReviewPaper

Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review

ReviewPaper

Current Approach to Dry Eye Disease

ReviewPaper

The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review

ReviewPaper

Ocular Involvement in Systemic Autoimmune Diseases

ReviewPaper

Vasculitides and the Complement System: a Comprehensive Review

OriginalPaper

IL-35 and Autoimmunity: a Comprehensive Perspective
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits